| Title |
Pioglitazone in Clinical Practice: Where Are We Now?
|
|---|---|
| Published in |
Diabetes Therapy, February 2012
|
| DOI | 10.1007/s13300-012-0001-z |
| Pubmed ID | |
| Authors |
Joytish Govindan, Marc Evans |
| Abstract |
Pioglitazone, a thiazolidinedione, improves insulin sensitivity and thus reduces blood glucose. Clinical trials have suggested potential cardiovascular outcome benefits in association with pioglitazone; however, safety concerns are mounting, with recent data suggesting a link between pioglitazone and an increased risk of bladder cancer. There is thus a growing focus on the risk-benefit profile of this agent and hence its potential role in the blood glucose-lowering treatment algorithm for people with type 2 diabetes. There are clear potential outcome benefits associated with pioglitazone. In this review, the authors focus on putting the true risk-benefit profile of pioglitazone into context based on critical appraisal of the currently available evidence. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 25 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 5 | 20% |
| Professor > Associate Professor | 4 | 16% |
| Student > Master | 3 | 12% |
| Student > Doctoral Student | 2 | 8% |
| Student > Postgraduate | 2 | 8% |
| Other | 3 | 12% |
| Unknown | 6 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 44% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 8% |
| Biochemistry, Genetics and Molecular Biology | 1 | 4% |
| Environmental Science | 1 | 4% |
| Agricultural and Biological Sciences | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 8 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 June 2012.
All research outputs
#18,304,874
of 22,663,150 outputs
Outputs from Diabetes Therapy
#708
of 1,007 outputs
Outputs of similar age
#120,686
of 155,482 outputs
Outputs of similar age from Diabetes Therapy
#1
of 3 outputs
Altmetric has tracked 22,663,150 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,007 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.4. This one is in the 4th percentile – i.e., 4% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 155,482 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them